Home > Insider Trading > Filing (0000950170-24-077944)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1650648	4D Molecular Therapeutics Inc.	FDMT	Biological Products, (No Disgnostic Substances) (2836)	473506994

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1834021	David Kirn	C/O 4D Molecular Therapeutics Inc. 5858 Horton Street #455 Emeryville CA 94608	Chief Executive Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-06-24	12,930	$14.42	1,072,083	No	4	M	Direct
Common Stock	Disposition	2024-06-24	12,930	$23.10	1,059,153	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right To Buy)	Disposition	2024-06-24	12,930	$0.00	12,930	$14.42

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
577,070		2033-12-10	No	4	M	Direct

Footnotes

Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 21, 2024.
The transaction was executed in multiple trades in prices ranging from $22.69 to $23.36, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of December 11, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.